Optimized HSP90 mediated fluorescent probes for cancer-specific bioimaging. Issue 9 (10th February 2020)

• Record Type: Journal Article
• Authors: Zhu, Shulei; Li, Yalei; Huang, Yushu; Zhang, Minmin; Gu, Xiaofan; He, Yang; Liu, Hongchun; Ma, Mingliang; Lu, Wei
• Is Part Of: Journal of materials chemistry. Volume 8:Issue 9(2020)
• Page Start: 1878
• Page End: 1896
• Publication Date: 2020-02-10
• Subjects: Materials -- Periodicals; Chemistry, Analytic -- Periodicals; Biomedical materials -- Research -- Periodicals; 543.0284
• DOI: 10.1039/c9tb02505g
• Languages: English
• ISSNs: 2050-750X

Abstract

Abstract : NP-001 is a promising imaging probe for detection and visualization of tumor lesions, offering low side effect and good biocompatibility. Abstract : Cancer-specific bioimaging has been correlated with fluorescence-guided tumor therapy, garnering extensive interest from researchers. Herein, a highly efficient tumor-targeting fluorescent probe (NP-001 ), which is integrated with 4-hydroxy-1, 8-naphthalimide and NVP-AUY922, for tumor imaging has been established. 4-Hydroxy-1, 8-naphthalimide is a fluorescent molecule with remarkable imaging compatibility. NVP-AUY922 is a heat shock protein 90 (HSP90) inhibitor with preferential tumor selectivity that is conjugated to 4-hydroxy-1, 8-naphthalimide as a tumor-targeting ligand. NP-002, a resorcinol-blocked probe which prevented binding with an amino acid residue of the HSP90 ATP binding pocket, was also synthesized as a control. In vitro and ex vivo assays showed that NP-001 could arrest cell proliferation, induce apoptosis and accumulate to inhibit HSP90. Confocal laser scanning microscopy (CLSM) also confirmed that NP-001 could be selectively internalized by tumor cells for cancer-specific bioimaging. Moreover, pharmacokinetic studies and histological analysis also indicated that NP-001 had a relatively longer retention time and showed no major organ-related toxicities. Overall, these encouraging data suggest that NP-001 is a promising new candidate for the early diagnosis of metastatic disease as well as targeted tumor imaging.